• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Graphite Bio Inc.

    3/28/24 4:30:24 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $GRPH alert in real time by email
    SC 13G 1 p24-1278sc13g.htm LENZ THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    LENZ Therapeutics, Inc.

    (Name of Issuer)
     

    Common stock, par value $0.00001 per share

    (Title of Class of Securities)
     

    52635N103

    (CUSIP Number)
     

    March 21, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 9 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 52635N10313GPage 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Alpha Wave Global, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,612,211

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,612,211

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,612,211

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    14.1%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

     

    CUSIP No. 52635N10313GPage 3 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Alpha Wave Ventures GP, Ltd

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,612,211

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,612,211

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,612,211

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    14.1%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 52635N10313GPage 4 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Chimera Investment LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Arab Emirates

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,612,211

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,612,211

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,612,211

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    14.1%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 52635N10313GPage 5 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Lunate Holding RSC LTD

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Arab Emirates

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,612,211

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,612,211

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,612,211

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    14.1%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 52635N10313GPage 6 of 9 Pages

     

     

    Item 1(a). Name of Issuer.
      LENZ Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
     

    611 Gateway Blvd., Suite 120

    South San Francisco, CA 94080

     

    Item 2(a). Name of Person Filing.
      This statement is being filed by Alpha Wave Global, LP (“Alpha Wave”), Alpha Wave Ventures GP, Ltd (“Alpha Wave Ventures GP”), Chimera Investment LLC (“Chimera”)  and Lunate Holding RSC LTD (“Lunate”, together with Alpha Wave Ventures GP, Alpha Wave and Chimera, the “Reporting Persons”) with respect to the securities held by Alpha Wave Ventures II, LP (“Alpha Wave Ventures”).
       
     

    Alpha Wave Ventures GP is the general partner of Alpha Wave Ventures. Alpha Wave Ventures GP is a joint venture between Alpha Wave and Lunate. Lunate is majority-owned by Chimera. Richard Gerson is the Chairman and Chief Investment Officer of Alpha Wave. Chimera is controlled by its board of directors. The managing partners of Lunate Capital Limited, a wholly-owned investment manager subsidiary of Lunate, manage the investment activities of Lunate.

       
      The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    Item 2(b). Address of Principal Business Office.
      The principal business office of Alpha Wave and Alpha Wave GP is 667 Madison Avenue, 19th Floor, New York, NY 10065. The principal business office for Chimera is Office 410, Royal Group Headquarters Building, Khalifa Park Area, Abu Dhabi, United Arab Emirates. The principal business office for Lunate is Unit No. 1, Floor 12, Al Maryah Tower, Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, United Arab Emirates.

     

    Item 2(c). Place of Organization.
      Alpha Wave is a Delaware limited partnership. Alpha Wave GP is an exempted limited company organized under the laws of the Cayman Islands. Chimera is organized under the laws of the United Arab Emirates. Lunate is a company organized under the laws of the Abu Dhabi Global Market in the United Arab Emirates.

     

    Item 2(d). Title of Class of Securities.
      Common stock, par value $0.00001 per share (the “Common Stock”)
       

     

    Item 2(e). CUSIP Number.
     

    52635N103

     

    CUSIP No. 52635N10313GPage 7 of 9 Pages

     

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

    Item 4. Ownership.
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentages set forth in this Schedule 13G are calculated based upon 25,533,533 shares of Common Stock outstanding as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 22, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      See Item 2(a).  

     

    CUSIP No. 52635N10313GPage 8 of 9 Pages

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 52635N10313GPage 9 of 9 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  March 28, 2024  
      Alpha Wave Global, LP
       
      By: /s/ Richard Gerson
      Name:  Richard Gerson
      Title:    Richard Gerson, Chairman and CIO
       
       
      Alpha Wave Ventures GP, Ltd
       
      By: /s/ Richard Gerson
      Name:  Richard Gerson
      Title:    Director
       
       
      Chimera Investment LLC
       
      By: /s/ Syed Basar Shueb Syed Shueb
      Name:  Syed Basar Shueb Syed Shueb
      Title:    Director and Authorized Signatory
       
      Lunate Holding RSC LTD
       
      By: /s/ Syed Basar Shueb Syed Shueb
      Name:  Syed Basar Shueb Syed Shueb
      Title:    Director and Authorized Signatory

     

    Get the next $GRPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRPH

    DatePrice TargetRatingAnalyst
    2/23/2023$3.00 → $2.00Neutral → Underperform
    BofA Securities
    2/23/2023$3.00Overweight → Neutral
    Cantor Fitzgerald
    2/23/2023Outperform → Market Perform
    Cowen
    1/25/2023Buy → Neutral
    BTIG Research
    1/18/2023$7.00 → $3.00Buy → Neutral
    BofA Securities
    1/6/2023$11.00 → $2.00Outperform → Mkt Perform
    SVB Leerink
    1/6/2023$14.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    9/15/2022$12.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $GRPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Graphite Bio Appoints Alethia Young as Chief Financial Officer

      Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins Graphite Bio from Cantor Fitzgerald, where she served as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. In this newly created position, Ms. Young will oversee the company's finance, investor relations and corporate communications functions, and will play a key role in overall corporate strategy. "On behalf of the e

      3/2/22 8:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)

      3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/28/24 4:31:03 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • LENZ Therapeutics and Graphite Bio Announce Merger Agreement

      - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

      11/15/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

      10/30/23 7:00:00 AM ET
      $GRPH
      $PEAK
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    SEC Filings

    See more

    $GRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $GRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 424B3 filed by Graphite Bio Inc.

      424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/9/24 4:18:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Graphite Bio Inc.

      10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 5:11:18 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 4:05:56 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by BofA Securities with a new price target

      BofA Securities downgraded Graphite Bio from Neutral to Underperform and set a new price target of $2.00 from $3.00 previously

      2/23/23 8:58:13 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Graphite Bio from Overweight to Neutral and set a new price target of $3.00

      2/23/23 8:56:04 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by Cowen

      Cowen downgraded Graphite Bio from Outperform to Market Perform

      2/23/23 6:14:16 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

      SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      4/8/24 2:46:09 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Graphite Bio Inc.

      SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:30:24 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Graphite Bio Inc.

      SC 13D - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:16:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Financials

    Live finance-specific insights

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • LENZ Therapeutics and Graphite Bio Announce Merger Agreement

      - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

      11/15/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

      10/30/23 7:00:00 AM ET
      $GRPH
      $PEAK
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate